AHA To HHS: Drug Makers Must Fully Cover Extra Costs From 340B Pilot

By Gabrielle Wanneh / September 9, 2025 at 5:31 PM

Hospitals want HHS to scrap its new 340B rebate model, but if the pilot proceeds, they demand the Health Resources and Services Administration (HRSA) require all drug companies that participate in the pilot that will test rebate payments over traditional upfront drug discounts to cover all costs associated with using rebates.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.